Esomeprazole + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Prevention

Conditions

Prevention

Trial Timeline

Feb 1, 2010 → Nov 1, 2011

NCT ID

NCT01069939

About Esomeprazole + Placebo

Esomeprazole + Placebo is a phase 3 stage product being developed by AstraZeneca for Prevention. The current trial status is completed. This product is registered under clinical trial identifier NCT01069939. Target conditions include Prevention.

What happened to similar drugs?

9 of 20 similar drugs in Prevention were approved

Approved (9) Terminated (0) Active (11)

✅RaltegravirMerckApproved

✅Meningococcal C conjugate vaccineNovartisApproved

✅Boostrix + Placebo (Saline)NovartisApproved

✅Meningococcal C conjugate vaccineNovartisApproved

✅Lenacapavir long-actingGilead SciencesApproved

✅DescovyGilead SciencesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01069939	Phase 3	Completed	Feb 1, 2010	Nov 1, 2011	Prevention
NCT00660660	Approved	Completed	Apr 1, 2008	Jul 1, 2008	Gastroesophageal Reflux Disease
NCT00542789	Phase 3	Completed	Aug 1, 2007	Feb 1, 2009	Gastric Ulcer
NCT00287339	Approved	Completed	Sep 1, 2005	Sep 1, 2008	Cough
NCT00745849	Pre-clinical	Completed	Jun 1, 2005	Mar 1, 2008	Vasomotor Rhinitis
NCT00628953	Phase 2	Completed	Oct 1, 2002	Apr 1, 2004	Asthma
NCT00628667	Approved	Completed	Feb 1, 2002	Mar 1, 2003	Chronic Posterior Laryngitis (CPL)

Competing Products

20 competing products in Prevention

See all competitors

Product	Company	Stage	Hype Score
mRNA-1944	Moderna	Phase 1	0
Gam-COVID-Vac	Dr. Reddy's Laboratories	Phase 2/3	31
edoxaban + enoxaparin sodium	Daiichi Sankyo	Phase 3	40
Mifepristone	Eli Lilly	Phase 2	35
EXANTA	AstraZeneca	Phase 2	27
Risk of low dose aspirin discontinuation	AstraZeneca	Pre-clinical	26
DAPA/MET XR + DAPA + MET XR	AstraZeneca	Phase 3	40
PCV15	Merck	Pre-clinical	18
Raltegravir	Merck	Approved	43
RotaTeq (V260) + IPV	Merck	Phase 3	40
V501	Merck	Phase 3	40
Zostavax	Merck	Phase 3	40
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920	Merck	Phase 3	40
Letermovir + Placebo	Merck	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
Enteric-coated mycophenolate sodium	Novartis	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
rMenB+OMV NZ	Novartis	Phase 3	40
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	40
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml	Novartis	Phase 3	44